Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Open Philanthropy
Deal Size : $2.3 million
Deal Type : Funding
Details : Exscientia will use the net proceeds to further explore the requirements for the activation of key aspects of the interferon response of known antiviral effects against influenza and COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Open Philanthropy
Deal Size : $2.3 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Queen Mary University of London
Deal Size : Undisclosed
Deal Type : Collaboration
TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL)
Details : The collaboration aims to research the therapeutic potential of gamma-delta T cells and their role in gut barrier protection against microbial infection and inflammation for the treatment of mucosal infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Queen Mary University of London
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $4.0 million
Deal Type : Funding
Details : The funding will support the development of next generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines using novel SpyVector platform. SpyVector is a platform based on recombinant adenovirus.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $4.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Unison Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Vernalis will use its expertise in drug discovery to design small molecules against this particularly challenging target, which has long been considered to be undruggable.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Unison Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Synthetic T-cell Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Department of Health and Social Care
Deal Size : $0.7 million
Deal Type : Funding
Details : The grant will cover the cost of generating a Chikungunya vaccine prototype. The project covers the identification of novel Chikungunya peptide epitopes (collectively constituting the “ligandome”), synthesis of a vaccine candidate and testing in in v...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 22, 2022
Lead Product(s) : Synthetic T-cell Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Department of Health and Social Care
Deal Size : $0.7 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $70.0 million
Deal Type : Collaboration
Details : The collaboration will initially focus on developing broad-spectrum Coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead program, which targets the main protease (Mpro) of SARS-CoV-2, the virus responsi...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $70.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : FairJourney Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies
Details : The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified potent neutralizing antibodies with distinct mechanisms of action.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : FairJourney Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $4.2 million
Deal Type : Funding
Details : Through this partnership, Exscientia will use its Centaur Biologist™ platform to apply domain-specific implementations of knowledge graphs and deep learning algorithms to a diverse wealth of biological data.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 12, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $4.2 million
Deal Type : Funding
Lead Product(s) : PRRSV vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : The Pirbright Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study investigating potential of solid-dose vaccine for porcine reproductive and respiratory syndrome virus (PRRSV) conducted in collaboration with The Pirbright Institute.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 29, 2020
Lead Product(s) : PRRSV vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : The Pirbright Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Astrazeneca Begins Efforts to Identify Antibodies Against Covid-19
Details : The applications were based on results from the Phase 3 CheckMate -9LA trial. In October 2019, the company announced the trial met its primary endpoint.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable